Acceleron Pharma (NASDAQ: XLRN) reported Q3 EPS of ($0.36), $0.10 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $4.16 million versus the consensus estimate of $4.38 million.

For earnings history and earnings-related data on Acceleron Pharma (XLRN) click here.